



Abstracts

Papers appearing in the October 2019 issue

A family with spinocerebellar ataxia and retinitis pigmentosa attributed to an *ELOVL4* mutation

Objective To identify the genetic cause of autosomal dominant spinocerebellar ataxia and retinitis pigmentosa in a large extended pedigree.

Methods Clinical studies were done at 4 referral centers. Ten individuals in the same extended family participated in at least a portion of the study. Records were obtained from an 11th, deceased, individual. Neurologic and dermatological examinations were performed. Ophthalmologic evaluation including fundoscopic examination and in some cases ocular coherence tomography were used to identify the presence of retinal disease. Whole exome sequencing (WES), in conjunction with Sanger sequencing and segregation analysis, was used to identify potential genetic mutation.

Results Affected individuals reported slowly progressive cerebellar ataxia with age at onset between 38 and 57. Imaging demonstrated cerebellar atrophy (3/3). WES identified a novel heterozygous mutation in the elongation of very long chain fatty acids 4 (*ELOVL4*) gene (c.512T > C, p.Ile171Thr) that segregated with ataxia in 7 members tested. Four of 8 members who underwent ophthalmologic evaluation were found to have retinitis pigmentosa. No skin findings were identified or reported. Ocular movement abnormalities and pyramidal tract signs were also present with incomplete penetrance.

Conclusions We report a family with both spinocerebellar ataxia and retinal dystrophy associated with an *ELOVL4* mutation. In addition, to supporting prior reports that *ELOVL4* mutations can cause spinocerebellar ataxia, our findings further broaden the spectrum of clinical presentations associated with spinocerebellar ataxia 34.

[NPub.org/NG/9323a](https://pubmed.ncbi.nlm.nih.gov/32323232/)

Homozygous pathogenic variant in *BRAT1* associated with nonprogressive cerebellar ataxia

Objective To investigate the pathogenicity of a novel homozygous *BRAT1* variant in 2 siblings with nonprogressive cerebellar ataxia (NPCA) through functional studies on primary and immortalized patient cell lines.

Methods *BRAT1* protein levels and ataxia-telangiectasia mutated (ATM) kinase activity in patient-derived and control cell lines were assessed by Western blotting. The impact of the novel *BRAT1* variants on mitochondrial function was also assessed, by comparing patient and control cell lines for rates of oxygen consumption and for phosphorylation (S293) of the E1 α subunit of pyruvate dehydrogenase (PDH).

Results Two male siblings with NPCA, mild intellectual disability, and isolated cerebellar atrophy were found to be homozygous for a c.185T>A (p.Val62Glu) variant in *BRAT1* by WES. Western blotting revealed markedly decreased *BRAT1* protein levels in lymphocytes and/or fibroblast cells from both affected siblings compared to control cell lines. There were no differences between the patient and control cells in ATM kinase activation, following ionizing radiation. Mitochondrial studies were initially suggestive of a defect in regulation of PDH activity, but there was no evidence of increased phosphorylation of the E1 α subunit of the PDH complex. Measurement of oxygen consumption rates similarly failed to identify differences between patient and control cells.

Conclusions Biallelic pathogenic variants in *BRAT1* can be associated with NPCA, a phenotype considerably milder than previously reported. Surprisingly, despite the molecular role currently proposed for *BRAT1* in ATM regulation, this disorder is unlikely to result from defective ATM kinase or mitochondrial dysfunction.

[NPub.org/NG/9323b](https://pubmed.ncbi.nlm.nih.gov/32323232/)



Most-Read Articles

As of October 3, 2019

KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients

J.J. Millichap, K.L. Park, T. Tsuchida, et al. 2016;2:e96. doi.org/10.1212/NXG.0000000000000096

Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk

B. Rhead, M. Bäärnhielm, M. Gianfrancesco, et al. 2016;2:e97. doi.org/10.1212/NXG.0000000000000097

The Clinical Outcome Study for dysferlinopathy: An international multicenter study

E. Harris, C.L. Bladen, A. Mayhew, et al. 2016;2:e89. doi.org/10.1212/NXG.0000000000000089

CHCHD10 variant p.(Gly66Val) causes axonal Charcot-Marie-Tooth disease

M. Auranen, E. Ylikallio, M. Shcherbii, et al. 2015;1:e1. doi.org/10.1212/NXG.0000000000000003

Phenotypic and molecular analyses of primary lateral sclerosis

H. Mitsumoto, P.L. Nagy, C. Gennings, et al. 2015;1:e3. doi.org/10.1212/01.NXG.0000464294.88607.dd

Neurology®

What's happening in *Neurology*® *Genetics*
Neurology 2019;93;1000
DOI 10.1212/WNL.00000000000008579

This information is current as of December 2, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/93/23/1000.full
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

